GoodRx (GDRX) Revenue & Revenue Breakdown
GoodRx Revenue Highlights
Latest Revenue (Y)
$750.26M
Latest Revenue (Q)
$200.61M
Main Segment (Y)
Prescription Transactions Revenue
GoodRx Revenue by Period
GoodRx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $750.26M | -2.12% |
| 2022-12-31 | $766.55M | 2.83% |
| 2021-12-31 | $745.42M | 35.36% |
| 2020-12-31 | $550.70M | 41.85% |
| 2019-12-31 | $388.22M | 55.59% |
| 2018-12-31 | $249.52M | - |
GoodRx generated $750.26M in revenue during NA 2023, up -2.12% compared to the previous quarter, and up 300.68% compared to the same period a year ago.
GoodRx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $200.61M | 1.38% |
| 2024-03-31 | $197.88M | 0.63% |
| 2023-12-31 | $196.64M | 9.27% |
| 2023-09-30 | $179.96M | -5.12% |
| 2023-06-30 | $189.68M | 3.09% |
| 2023-03-31 | $183.99M | -0.07% |
| 2022-12-31 | $184.11M | -1.71% |
| 2022-09-30 | $187.32M | -2.34% |
| 2022-06-30 | $191.80M | -5.67% |
| 2022-03-31 | $203.33M | -4.65% |
| 2021-12-31 | $213.26M | 9.30% |
| 2021-09-30 | $195.10M | 10.45% |
| 2021-06-30 | $176.63M | 10.10% |
| 2021-03-31 | $160.43M | 4.49% |
| 2020-12-31 | $153.54M | 9.32% |
| 2020-09-30 | $140.45M | 13.92% |
| 2020-06-30 | $123.30M | -7.58% |
| 2020-03-31 | $133.41M | 17.79% |
| 2019-12-31 | $113.26M | 11.31% |
| 2019-09-30 | $101.75M | 11.16% |
| 2019-06-30 | $91.53M | 5.68% |
| 2019-03-31 | $86.61M | - |
GoodRx generated $200.61M in revenue during Q2 2024, up 1.38% compared to the previous quarter, and up 109.04% compared to the same period a year ago.
GoodRx Revenue Breakdown
GoodRx Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Subscription Revenue | $94.41M | $96.17M | $59.92M | - |
| Other Revenue | $20.05M | $20.43M | $92.14M | $62.44M |
| Prescription Transactions Revenue | $550.74M | $550.54M | $593.36M | $488.26M |
GoodRx's latest annual revenue breakdown by segment (product or service), as of Dec 23: Prescription Transactions Revenue (82.79%), Subscription Revenue (14.19%), and Other Revenue (3.01%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Revenue | $5.38M | $5.23M | $5.39M | $4.93M | $4.50M | $5.17M | $5.15M | $4.86M | $5.24M | $37.09M | $23.22M | $17.46M | $26.37M | $22.24M | $16.07M |
| Subscription Revenue | $22.60M | $23.15M | $23.24M | $23.88M | $24.14M | $24.62M | $26.45M | $25.98M | $19.11M | $17.38M | $16.23M | $14.32M | - | - | - |
| Prescription Transactions Revenue | $145.40M | $143.86M | $135.43M | $136.54M | $134.91M | $129.41M | $131.22M | $134.40M | $155.51M | $158.79M | $155.65M | $144.86M | $134.06M | $131.31M | $124.39M |
| Pharma Manufacturer Solutions Revenues | - | - | - | $24.33M | $20.43M | $24.50M | $26.55M | $23.47M | - | - | - | - | - | - | - |
GoodRx's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Prescription Transactions Revenue (83.86%), Subscription Revenue (13.04%), and Other Revenue (3.10%).
GoodRx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GEHC | GE HealthCare | $19.55B | $4.84B |
| TDOC | Teladoc Health | $2.60B | $642.44M |
| VEEV | Veeva Systems | $2.36B | $650.35M |
| EVH | Evolent Health | $1.96B | $647.14M |
| PRVA | Privia Health Group | $1.66B | $422.33M |
| PGNY | Progyny | $1.09B | $304.09M |
| GDRX | GoodRx | $750.26M | $200.61M |
| TXG | 10x Genomics | $618.73M | $153.10M |
| DOCS | Doximity | $475.42M | $126.68M |
| ACCD | Accolade | $414.29M | $110.47M |
| CERT | Certara | $354.34M | $93.31M |
| HCAT | Health Catalyst | $295.94M | $74.72M |
| HSTM | HealthStream | $279.06M | $71.56M |
| DH | Definitive Healthcare | $251.41M | $63.70M |
| SDGR | Schrödinger | $216.67M | $47.33M |
| TALK | Talkspace | $150.04M | $46.06M |
| NRC | National Research | $148.58M | $35.31M |
| SLP | Simulations Plus | $59.58M | $18.54M |
| AMWL | American Well | - | - |
GDRX Revenue FAQ
What is GoodRx’s yearly revenue?
GoodRx's yearly revenue for 2023 was $750.26M, representing a decrease of -2.12% compared to 2022. The company's yearly revenue for 2022 was $766.55M, representing an increase of 2.83% compared to 2021. GDRX's yearly revenue for 2021 was $745.42M, representing an increase of 35.36% compared to 2020.
What is GoodRx’s quarterly revenue?
GoodRx's quarterly revenue for Q2 2024 was $200.61M, a 1.38% increase from the previous quarter (Q1 2024), and a 5.76% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $197.88M, a 0.63% increase from the previous quarter (Q4 2023), and a 7.55% increase year-over-year (Q1 2023). GDRX's quarterly revenue for Q4 2023 was $196.64M, a 9.27% increase from the previous quarter (Q3 2023), and a 6.81% increase year-over-year (Q4 2022).
What is GoodRx’s revenue growth rate?
GoodRx's revenue growth rate for the last 3 years (2021-2023) was 0.65%, and for the last 5 years (2019-2023) was 93.26%.
What are GoodRx’s revenue streams?
GoodRx's revenue streams in c 23 are Subscription Revenue, Other Revenue, and Prescription Transactions Revenue. Subscription Revenue generated $94.41M in revenue, accounting 14.19% of the company's total revenue, down -1.83% year-over-year. Other Revenue generated $20.05M in revenue, accounting 3.01% of the company's total revenue, down -1.83% year-over-year. Prescription Transactions Revenue generated $550.74M in revenue, accounting 82.79% of the company's total revenue, up 0.04% year-over-year.
What is GoodRx’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of GoodRx was Prescription Transactions Revenue. This segment made a revenue of $550.74M, representing 82.79% of the company's total revenue.